Dose Ranging Study of RPL554 in Chronic Obstructive Pulmonary Disease (COPD) Patients
Clinical trial NCT03443414 · COMPLETED
Trial details
- NCT number
- NCT03443414
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-06-01
- Primary completion
- 2018-01-23
- Enrollment
- 405
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.